Figure 2.
(A) Meta-analysis of overall survival with high HHLA2 expression in comparison to low HHLA2 expression in 2659 patients with solid tumors, as estimated by random effect model due to moderate heterogeneity among studies (I2 65%). The summary HR shows unfavorable prognosis in the group with increased HHLA2 expression (HR 1.58, 95% CI: 1.23–2.03, p = 0.0003). Studies differed significantly in cut-off values for dichotomizing high and low expression (Supplementary Materials Figure S6). (B) One-leave meta-analysis for investigating the effects of removing single study from analysis on the association between HHLA2 expression and overall survival in solid tumors. Excluding a particular study from the meta-analysis did not result in significant effect on the overall survival.